Please Wait.....
Report
Bayer Aktiengesellschaft (Bayer AG) (BAYN:GER) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends
Company Report I 2024-09-19 I 97 Pages I Quaintel Research
Report Summary
Bayer Aktiengesellschaft (Bayer AG) (BAYN:GER) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends Report is a comprehensive and easily accessible overview of Bayer Aktiengesellschaft (Bayer AG)'s business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Bayer Aktiengesellschaft (Bayer AG) including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Bayer Aktiengesellschaft (Bayer AG)'s strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Bayer Aktiengesellschaft (Bayer AG)'s overall strategic standing and supports informed decision-making and strategic planning.
The report also covers Bayer Aktiengesellschaft (Bayer AG)'s financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Bayer Aktiengesellschaft (Bayer AG)'s financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by Bayer Aktiengesellschaft (Bayer AG) enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Bayer Aktiengesellschaft, commonly known as Bayer AG, is a global enterprise with core competencies in the life science fields of health care and agriculture. Established in 1863, the company is headquartered in Leverkusen, Germany. Bayer operates in two main divisions: Bayer Pharmaceuticals and Bayer CropScience.
Bayer Pharmaceuticals focuses on research and development in pharmaceuticals, including prescription medications for various therapeutic areas such as cardiology, oncology, gynecology, and hematology. The division is known for its innovative drugs and commitment to addressing unmet medical needs. Bayer's portfolio includes notable products such as aspirin, a revolutionary medication that has had a profound impact on pain relief and cardiovascular health.
Bayer CropScience is dedicated to agriculture and provides solutions that support farmers and promote sustainable agricultural practices. This division develops and markets crop protection products, seeds, and traits to enhance crop yield and quality. Bayer is a leader in integrated pest management and offers solutions that help manage agricultural pests and diseases.
The company is committed to sustainability and strives to create value for its stakeholders while minimizing environmental impact. Bayer engages in numerous initiatives to promote health and well-being, including efforts in environmental conservation and corporate social responsibility.
Bayer Aktiengesellschaft (Bayer AG) in the News:-
- 16-Sep-2024 - Darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT in patients with mHSPC
- 11-Sep-2024 - Eylea 8 mg data at EURETINA demonstrate durability, rapid and sustained fluid control and emphasize safety profile
- 10-Sep-2024 - Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause
- 10-Sep-2024 - New subgroup analysis from FINEARTS-HF revealed patients with heart failure and a left ventricular ejection fraction of ?40% receiving finerenone had a reduced risk of new-onset diabetes
- 09-Sep-2024 - New results from the Investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the Bayer Aktiengesellschaft (Bayer AG)'s internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Bayer Aktiengesellschaft (Bayer AG):
- Bayer Aktiengesellschaft (Bayer AG) Value Chain Analysis
- Bayer Aktiengesellschaft (Bayer AG) Porter's Five Forces Analysis
- Bayer Aktiengesellschaft (Bayer AG) VRIO Analysis
- Bayer Aktiengesellschaft (Bayer AG) BCG Analysis
- Bayer Aktiengesellschaft (Bayer AG) Segmentation, Targeting and Positioning (STP) Analysis
- Bayer Aktiengesellschaft (Bayer AG) Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
Bayer Aktiengesellschaft (Bayer AG) - Key Company Facts 8
Bayer Aktiengesellschaft (Bayer AG) - Company Description 9
Bayer Aktiengesellschaft (Bayer AG) - Top Executives 10
Bayer Aktiengesellschaft (Bayer AG)- Head Office & Locations 12
Head Office - Country 12
Bayer Aktiengesellschaft (Bayer AG) - Products and Services 13
Products 13
Bayer Aktiengesellschaft (Bayer AG) - Company's Mission and Vision 14
Mission 14
Vision 14
Bayer Aktiengesellschaft (Bayer AG) - Corporate Strategy 15
Bayer Aktiengesellschaft (Bayer AG) - Business Description 17
Pharmaceuticals 17
Consumer Health 17
Crop Science 18
Bayer Aktiengesellschaft (Bayer AG) - ESG Spotlight 19
Environment 19
Social 20
Corporate Governance 20
Bayer Aktiengesellschaft (Bayer AG) - SWOT Analysis 21
Overview 21
Strengths 23
Weaknesses 25
Opportunities 26
Threats 29
Bayer Aktiengesellschaft (Bayer AG) - PESTLE Analysis 31
Overview 31
Political Factors 33
Economic Factors 36
Social Factors 38
Technological Factors 40
Legal Factors 42
Environmental Factors 43
Bayer Aktiengesellschaft (Bayer AG) - Financial Deep Dive 45
Share Price Trend - Sep-2023to Sep-2024 (Average Share Closing Price) 45
Profit and Loss Statement 47
Summary of Profit and Loss Statement 47
Balance Sheet 49
Summary of Balance Sheet 49
Cash Flow Statement 51
Summary of Cash Flow Statement 51
Key Financial Ratio Analysis 53
Bayer Aktiengesellschaft (Bayer AG) - Ratio Charts 54
Activity Ratio Charts 54
Growth Ratios Charts 55
Leverage Ratio Charts 56
Liquidity Ratio Charts 56
Profitability Ratio Charts 58
Competing Players 59
Snapshot of Competing Players 60
Johnson & Johnson 60
Key Company Facts 60
Company Description 60
Snapshot of Competing Players 62
Novartis AG 62
Key Company Facts 62
Company Description 62
Snapshot of Competing Players 64
Pfizer Inc. 64
Key Company Facts 64
Company Description 64
Snapshot of Competing Players 66
Merck & Co., Inc. 66
Key Company Facts 66
Company Description 66
Snapshot of Competing Players 68
GlaxoSmithKline Pharmaceuticals Ltd 68
Key Company Facts 68
Company Description 68
Bayer Aktiengesellschaft (Bayer AG) - In the News 70
16-Sep-2024- Darolutamide plus ADT significantly reduced the risk of radiological progression or death compared to placebo plus ADT in patients with mHSPC 70
11-Sep-2024- Eylea 8 mg data at EURETINA demonstrate durability, rapid and sustained fluid control and emphasize safety profile 72
10-Sep-2024- Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause 77
10-Sep-2024- New subgroup analysis from FINEARTS-HF revealed patients with heart failure and a left ventricular ejection fraction of ?40% receiving finerenone had a reduced risk of new-onset diabetes 79
09-Sep-2024- New results from the Investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC 81
05-Aug-2024- Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction 83
01-Aug-2024- Bayer submits New Drug Application to U.S. FDA for elinzanetant for the treatment of moderate to severe vasomotor symptoms associated with menopause 84
23-Jul-2024- Vividion Therapeutics to Expand with New Global Research and Development Center 86
23-Jul-2024- Darolutamide meets primary endpoint in Phase III ARANOTE trial in men with metastatic hormone-sensitive prostate cancer 88
11-Jul-2024- AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease 89
Appendix 91
Definitions 91
SWOT Analysis 91
PESTLE Analysis 91
Value Chain Analysis 91
ESG Spotlight 91
Financial Deep Dive 91
Financial Ratios - 92
Activity Ratios 92
Growth Ratios 93
Leverage Ratios 94
Liquidity Ratios 95
Market Ratios 96
Profitability Ratios 96
Research Methodology 97
Disclaimer 98
Contact Us 98
Tables
Table 1: Bayer Aktiengesellschaft (Bayer AG) - Company Facts
Table 2: Bayer Aktiengesellschaft (Bayer AG) - Top Executives
Table 3: Bayer Aktiengesellschaft (Bayer AG) - Products
Table 4: Bayer Aktiengesellschaft (Bayer AG) - Share Price Trend - Sep-2023 to Sep-2024
Table 5: Bayer Aktiengesellschaft (Bayer AG)- Ratio Analysis - 2020-2023
Table 6: Bayer Aktiengesellschaft (Bayer AG) -Competing Players
Charts
Figure 1: Bayer Aktiengesellschaft (Bayer AG)- SWOT Analysis 22
Figure 2: Bayer Aktiengesellschaft (Bayer AG) - PESTLE Analysis 32
Figure 3: Bayer Aktiengesellschaft (Bayer AG) - Average Share Price Trend - Sep-2023 to Sep-2024 46
Figure 4: Bayer Aktiengesellschaft (Bayer AG) - Profit and Loss Statement - 2020-2023 48
Figure 5: Bayer Aktiengesellschaft (Bayer AG) - Balance Sheet - 2020-2023 50
Figure 6: Bayer Aktiengesellschaft (Bayer AG) - Cash Flow Statement 2020-2023 52
Figure 7: Bayer Aktiengesellschaft (Bayer AG) - Activity Ratio Charts 54
Figure 8: Bayer Aktiengesellschaft (Bayer AG) - Growth Ratio Charts (Value %) 55
Figure 9: Bayer Aktiengesellschaft (Bayer AG) - Leverage Ratio Charts 56
Figure 10: Bayer Aktiengesellschaft (Bayer AG) - Liquidity Ratio Charts 57
Figure 11: Bayer Aktiengesellschaft (Bayer AG) - Profitability Ratio Charts (Value %) 58
Figure 12: Competing Players - Johnson & Johnson - Key Financials 61
Figure 13: Competing Players - Novartis AG - Key Financials 63
Figure 14: Competing Players - Pfizer Inc. - Key Financials 65
Figure 15: Competing Players - Merck & Co., Inc. - Key Financials 67
Figure 16: Competing Players - GlaxoSmithKline Pharmaceuticals Ltd - Key Financials 69
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security